A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Conditions

Pancreas

Phase 1B/2

What is the purpose of this trial?

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

  • Trial with
    Eli Lilly and Company
  • Start Date
    11/29/2018
  • End Date
    12/01/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Rebecca Lilian

  • Last Updated
    05/06/2019
  • Study HIC
    #2000022550